Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.
The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments